Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for severe neurological diseases. Its pipeline includes programs for Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases. The Company's clinical-stage programs include VY-AADC for Parkinson's disease, VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. The Company's preclinical programs include VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-TAU01 for Alzheimer's disease, and VY-NAV01 for severe chronic pain. The Company's gene therapy platform includes adeno-associated virus (AAV) vectors, which are naturally occurring, non-pathogenic viruses that are capable of delivering genetic material to cells. The Company has collaborations with Sanofi Genzyme, AbbVie, and Neurocrine Biosciences, Inc.